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Abstract 
 
Purpose: Detection of microaneurysms and/or microhaemorrhages near the fovea when screening 
for diabetic retinopathy (DR) poses a problem because referral to retinal specialists may alarm 
patients and unnecessarily burden ophthalmologists.  
Methods: Six-month prospective study of patients found to have minimal red lesions within one 
disc diameter of the fovea when screened for DR. Two 45° digital photographs, one centred on the 
macula and the other nasal including the optic disc, were taken for each eye. All patients received a 
6-month re-screening appointment. 
Results: Out of 70 patients, 41 returned for re-screening. DR had worsened in 3, who required 
referral but no treatment, was unchanged in 19 and undetectable in the other 19. HbA1c decreased 
from 7.76±1.50% (61.3±16.2 mmol/mol) to 6.93±1.7 (52.3±18.9  mmol/mol) in the patients in 
whom DR worsened but did not change in the other groups. Baseline HbA1c (p=0.048) and systolic 
blood pressure (p=0.007) were lower in the patients in whom DR improved, but a multivariate 
model including HbA1c, blood pressure and known disease duration could not identify any 
independent risk factor. 
Conclusion: Minimal red lesions near the fovea, though commanding early re-screening, do not 
require immediate referral to retinal specialists.  
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 Introduction 
Screening for sight-threatening retinopathy ranks among the most cost-effective procedures in 
health care (1,2). Protocols and guidelines are well in place (3-5) but evidence for some aspects of 
the screening process remains to be strengthened. In particular, little is published on how to proceed 
when isolated red lesions, i.e. microaneurysms and/or microhaemorrhages, are identified by retinal 
photography near the fovea (6,7). On the one side, since the macula is the centre of vision, minimal 
lesions should not be overlooked by graders, especially if they are not retinal specialists, when 
screening is carried out on bi-dimensional colour photographs which do not permit detection of 
retinal thickening and macular edema. On the other hand, referral of minimal lesions may place 
unnecessary burden on retinal specialists and alarm on patients. 
Based on these premises, a prospective observational study was carried out in patients who, when 
screened in our Diabetic Retinopathy Centre, were found to have red lesions within one optic disc 
diameter of the centre of the fovea, in the absence of other signs of more severe DR. 
 
Methods 
Screening for diabetic retinopathy (DR) in our Centre includes collection of clinical data, 
measurement of visual acuity by decimal charts and intraocular pressure by insufflation tonometry, 
and induction of mydriasis by 1% tropicamide eye drops. Two 45° digital photographs of the retina 
are taken by a Kowa Pro-II funduscamera, one centred on the macula and the other nasal to, though 
including, the optic disc. All images were visualized by the EyeCap software (Haag-Streit, Koeniz, 
Switzerland), evaluated by a medically qualified grader (AB) and included in this study if they 
showed any red dots and blots within one disc diameter of the centre of the fovea. Exclusion criteria 
were: previous evidence of DR involving the macular area, presence of hard exudates or any other 
lesions requiring referral according to Italian guidelines (5), previous retinal treatment by 
photocoagulation and/or intraocular agents, presence of other systemic conditions, e.g. renal failure 
or cancer, potentially impacting on retinal status and/or shortening life expectancy.  
According to current Italian guidelines (5), patients with mild non proliferative DR at the posterior 
pole were given a 6-month appointment for re-screening, which included the procedure described 
above and grading by the same observer. The lesions were classified as improved if no longer 
visible, stable if still detectable on the images, and worse if larger/more numerous than at baseline. 
Worsening of DR involved referral to an ophthalmologist whereas persistence/improvement of the 
lesions observed at baseline indicated another 6-month screening appointment. Enrolment was from 
January 2015 through to March 2017. All photographs were reviewed by a second independent 
grader (MP) and, in the case of discordance, discussed and adjudicated by the two graders together.  
Diabetes was classified as type 1 if onset had been before age 30 and insulin started within 1 year of 
diagnosis, and type 2 if onset had been after age 40 and insulin treatment was either not in place or 
started more than 1 year after diagnosis. 
Ethical clearance for the study and informed consent were obtained from the patients, according to 
the tenets of the Helsinki Declaration. 
 
Statistical analysis. Descriptive data are shown as absolute and relative frequencies of the different 
modalities for categorical data and as mean ± standard deviation (SD) for continuous variables. At 
univariate analysis, t-test for continuous variables and chi-square test for qualitative variables were 
carried out to detect the possible predictors of DR progression by comparing clinical characteristics 
at baseline between the improved and stable/worsened group. Multivariable analysis models were 
then fitted to evaluate the independent effect of the variables that turned out to be significantly 
associated to DR status at univariate analysis: DR group at 6 months (stable/worsened versus 
improved group) was set as the dependent variable of a logistic regression model where known 
diabetes duration, systolic blood pressure and HbA1c at baseline were taken as independent 
variables. For all tests, a p value of less than 0.05 was considered significant. All analyses were 
performed with Stata 14. 
 
Results 
In total, 70 patients were enrolled, 42 men and 28 women, 17 with type 1 diabetes, 52 with type 2 
and 1 with secondary post-pancreatectomy diabetes. Mean age was 56.7 ± 15.7 and known disease 
duration 15.0 ± 10.6 years. Of these, 41 returned for the 6-month re-screening visit. DR had 
worsened in 3 of them and required referral, was unchanged in 19, and undetectable in the 
remaining 19.  
All 3 patients in whom DR worsened had type 2 diabetes. Two were females, age was 60.3 ± 2.5, 
known diabetes duration 8.7 ± 5.5 years, and systolic blood pressure 142.3 ± 15.3. Their serum 
creatinine was 0.81 ± 0.38 mg/dl (eGFR 107.3 ± 30.2 ml/min), serum cholesterol 161.3 ± 28.2 
mg/dl, HDL cholesterol 51.7 ± 12.1 mg/dl, and trigyceride 135.0 ± 27.0 mg/dl. Interestingly, the 
mean HbA1c of these 3 patients had decreased from 7.76 ± 1.50% (61.3 ± 16.2 mmol/mol) at 
baseline to 6.93 ±  1.7 after 6 months (52.3 ± 18.9  mmol/mol) while it did not change in the other 
two groups. Of these 3 patients, 2 were on oral agents and 1 on insulin, 2 on inhibitors of the renin-
angiotensin system and none on statins. 
Because of the low numbers, for statistical purposes, the 3 patients in whom DR had worsened were 
grouped with the 19 in whom DR had remained stable and compared for risk determinants with 
those in whom the lesions had cleared. The clinical characteristics of these two groups are shown in 
Table 1. 
Univariate analysis showed that baseline HbA1c (p=0.048) and systolic blood pressure (p=0.007) 
were lower in the patients in whom DR had improved over the following 6 months. However, a 
multivariate analysis model including these two variables and known disease duration could not 
identify any independent risk factor (Table 2). 
Eighteen patients returned for screening after 12 months of baseline, of whom 1 had not attended at 
6 months, but in none of them had DR worsened. 
 
Discussion 
This study shows that minimal lesions (red dots and blots) detected by digital retinal photography in 
the macular area at the time of screening for DR do not warrant immediate referral to an 
ophthalmologist. Of the patients with these characteristics, only 3 deteriorated marginally to require 
specialist attention but did not proceed to photocoagulation or other forms of treatment for DR, 
whereas the lesions either stabilised or even disappeared over 6 months in the other patients. These 
findings are in line with the results of two other studies that investigated similar groups of patients 
although considering only ophthalmological outcomes. One of them was also prospective and 
reported no development of clinically significant macular edema over 9-months of follow-up (6). 
The other was a cross-sectional study in which patients with minimal peri-foveal lesions were 
evaluated by optical coherence tomography (OCT), reporting that suspicion of macular involvement 
on the basis of retinal photography alone carries a false-positive rate of 86.6% (7). In this paper, we 
also collected a series of clinical data to search for possible systemic risk factors associated with the 
outcome of such retinal lesions. 
This study has limitations. The number of patients enrolled is low but, as this clinic has a turnover 
of about 3,000 screening episodes per year, the fact that it took more than 2 years to collect the 
sample is testimony to the relative rarity of the condition investigated. This limited the possibilities 
of identifying clinical risk factors that would help to single out patients at risk of progression of DR. 
As expected, those who regressed had lower systolic blood pressure and HbA1c, in line with the 
literature (8), but neither remained as an independent risk factor when multivariate analysis was 
carried out. Nevertheless, special care should be applied to bring these variables to target, if 
elevated. On the other hand, the 3 patients whose DR worsened did not have poor control of blood 
pressure or high HbA1c to start with. Indeed, their HbA1c decreased to a larger extent than in the 
other patients. The relatively modest rate of HbA1c decrease suggests but does not fully support a 
phenomenon of “early worsening” of DR, which was described for larger rapid improvements of 
metabolic control in type 1 (9) and type 2 diabetes (10). Measurements of retinal thickness by 
Optical Coherence Tomography (OCT) should have complemented the study of these patients (7), 
but the instrument was not available to us for screening purposes. Assessment of DR was on bi-
dimensional digital photographs by two expert medically qualified graders and there was no 
significant drop in visual acuity. Finally, the dropout rate of 29 patients who, out of 70, failed to 
return for their 6-month appointment, despite being warned that a potentially serious condition was 
detected in their eyes, is worrying and points to the need for efficient recall mechanisms to be put in 
place.  
In conclusion, this study confirms that presence of minimal red lesions near the fovea, though 
commanding early re-screening, does not require immediate referral to retinal specialists. 
Potentially, the addition of OCT to the screening procedure, may help identify patients in need of 
stricter follow up.  
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Table 1. Comparison of the patients in whom DR improved and in whom DR remained stable 
or worsened.  
 Improved (n=19) 
Baseline 
Stable/Worsened (n=22) 
Baseline 
 p value* 
Type 1 diabetes 
Type 2 diabetes 
4 
15 
4 
18 0.817 
Males 10 (52.6%) 14 (63.6%) 0.476 
Active smokers 11 (57.9%) 12 (54.6%) 0.427 
Age (years) 58.2 ± 15.6 59.2 ±  11.9 0.814 
Known duration of 
diabetes (years) 
14.3 ± 10.1 16.3 ± 10.2 0.532 
Treatment: 
Diet only 
 Oral agents 
 Insulin 
 Oral agents + insulin 
 
0 (0%) 
11 (57.9%) 
4 (21.1%) 
4 (21.1%) 
 
1 (4.5%) 
12 (54.6%) 
5 (22.7%) 
4 (18.2%) 
 
0.816 
 
 Baseline 6 months Baseline 6 months  
BMI 28.5 ± 4.9 28.1 ± 5.0 28.3 ± 4.5 28.4 ± 4.6 0.875 
HbA1c(%) 7.1 ± 0.9 7.0 ± 1.1 8.6 ± 2.7 8.1 ± 2.7 0.048 
HbA1c (mmol/mol) 54.3 ± 9.7 52.9 ± 12.4 69.9 ± 28.9 64.6 ± 28.6 0.048 
Systolic blood 
pressure (mmHg) 
130.2 ± 13.7 129.8 ± 14.9 145.4 ± 18.4 141.9 ± 20.1 0.007 
 
Diastolic blood 
pressure (mmHg) 
77.4 ± 12.0 77.4 ± 12.5 79.6 ± 9.7 81.4 ± 13.4 0.534 
 
Serum creatinine 
(mg/dl/) 
0.91 ± 0.3 0.89 ± 0.33 0.79 ± 0.2 0.81 ± 0.2 0.174 
eGFR (ml/min) 94.1 ± 35.51 95.1 ± 36.8 101.3 ± 26.2 101.78 ± 
34.8 
0.492 
Total cholesterol 
(mg/dl/) 
168 ± 30.59 162.6 ± 29.8 173.2 ± 40.9 170.4 ± 47.3 0.680 
HDL cholesterol 
(mg/dl/) 
55.7 ± 18.3 53.3 ± 17.8 57.2 ± 17.4 57.1 ± 14.3 0.811 
Triglyceride (mg/dl/) 107.1 ± 39.9 110.4 ± 45.2 123.6 ± 58.4 104.8 ± 42.4 0.345 
On ACEi/ARB              6 (31.6%) 6 (31.6%) 9 (42.9%) 10 (45.5%) 0.635 
On statins 5 (27.8%) 5 (27.8%) 6 (27.3%) 6 (27.3%) 0.955 
DR – Right eye 
          Left eye 
          Both eyes 
          Absent 
  9 (47.4%) 
10 (52.6%) 
0 
0 
0 
0 
0 
19 (100%) 
12  (54.5%) 
  6  (27.3%) 
  4  (18.2%) 
0 
11 (50%) 
    8 (36.4%) 
    3 (13.6%) 
0 
 
0.113 
 
*p-values refer to comparisons between the patient groups at baseline 
 Table 2. Multivariate analysis for DR progression predictors. 
Clinical characteristics at baseline Odds Ratio 95% CI p value 
Known diabetes duration .98 .89-1.07 0.702 
 
Systolic blood pressure 1.04 .99-1.10 0.068 
 
HbA1c 2.16 .78-5.99 0.139 
 
 
 
